Karen Mulder

Contact Overview Publications

Contact

Faculty of Medicine & Dentistry - Oncology Dept

Email: kmulder@ualberta.ca
Phone: (780) 432-8248
Address: Cross Cancer Institute
11560 University Avenue

Edmonton AB

T6G 1Z2

Overview

Area of Study / Keywords

About

Mulder obtained her medical degree at the University of Alberta. She is certified by the Royal College of Physicians and Surgeons of Canada as a specialist in Internal Medicine with subspecialty training in Medical Oncology. Mulder is a medical oncologist who specializes in the treatment of gastrointestinal malignancies and soft tissue malignancies. She has been the CCI site leader for the Musculoskeletal (Sarcoma) Tumour Group since April 2005.

Research

Clinical research in patients with gastrointestinal malignancies and sarcomas; Phase II/III clinical trials.

Pharmacogenomic research. Studying how an individual’s genetic inheritance affects their body’s response to drugs in colon cancer patients.

Featured Publications

Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers�A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference

Mulder K., Lim H., Ravi D., Ahmed S., Brunet B., Davies J., Doll C., Dueck D.A., Gordon V., Hebbard P., Kim C.A., Le D., Lee-Ying R., McGhie J.P., Park J., Renouf D.J., Schellenberg D., Wong R.P.W., Zaidi A., Ahmed S.

Current Oncology. 2022 May; 29 (5):3160-3170 10.3390/curroncol29050257

Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference

Ahmed S., Bosma N., Moser M., Ahmed S., Brunet B., Davies J., Doll C., Dueck D.A., Kim C.A., Ji S., Le D., Lee-Ying R., Lim H., McGhie J.P., Mulder K., Park J., Ravi D., Renouf D.J., Schellenberg D., Wong R.P.W., Zaidi A.

Current Oncology. 2022 March; 29 (3):1796-1807 10.3390/curroncol29030147

Are two too many when it comes to treatment of anal canal cancer with concurrent radiation and mitomycin C?

Journal of Clinical Oncology 2022 ASCO Gastrointestinal Cancer Symposium. 2022 February; 10.1200/JCO.2022.40.4_suppl.003, Abstr 3

Report from the Western Canadian Gastrointestinal Consensus Cancer Conference�Management of Total Neoadjuvant Therapy in Rectal Cancer

Lim H., Abraham A.G., Ahmed S., Ahmed S., Brown C.J., Brunet B., Davies J., Doll C., Dueck D.A., Gordon V., Hagel K., Hebbard P., Kim C.A., Le D., Lee-Ying R., McGhie J.P., Mulder K., Park J., Renouf D.J., Schellenberg D., Wong R.P.W., Zaidi A.

Current Oncology. 2022 February; 29 (2):924-927 10.3390/curroncol29020078

Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?

Abraham A.G., Joseph K., Spratlin J.L., Zebak S., Alba V., Iafolla M., Ghosh S., Abdelaziz Z., Lui A., Paulson K., Bedard E., Chua N., Tankel K., Koski S., Scarfe A., Severin D., Zhu X., King K., Easaw J.C., Mulder K.E.

CLINICAL ONCOLOGY. 2022 January; 10.1016/j.clon.2022.05.011

Report from the western canadian gastrointestinal cancer consensus conference virtual education series�transition from local to system therapy and optimal sequencing of systemic therapy for hcc

Zaidi A., Ahmed S., Ahmed S., Brunet B., Davies J., Doll C., Dueck D.A., Gordon V., Hebbard P., Kim C., Le D., Lee-Ying R., Lim H., Liu D., McGhie J.P., Mulder K., Park J., Renouf D., Schellenberg D., Wong R.P.W., Moser M.

Current Oncology. 2021 December; 28 (6):4317-4327 10.3390/curroncol28060367

Five-year survival, toxicity, patient reported quality of life after intensity modulated radiation therapy-based concurrent chemoradiotherapy of locally advanced anal cancer.

Canadian Association of Radiation Oncology Virtual Scientific Meeting 2021. 2021 October;

Report from the 21st annual western canadian gastrointestinal cancer consensus conference; calgary, Alberta; 20-21 September 2019

Lee-Ying R., Ahmed O., Ahmed S., Ahmed S., Bathe O.F., Brunet B., Dawson L., Davies J., Gordon V., Hebbard P., Kasnik J., Kim C.A., Le D., Lee M.K.C., Lim H., McGhie J.P., Mulder K., Park J., Renouf D., Tam V., Visser R., Wong R.P.W., Zaidi A., Doll C.

Current Oncology. 2021 October; 28 (5):3629-3648 10.3390/curroncol28050310

The use of proton pump inhibitors does not adversely influence pathological and clinical outcomes when used with capecitabine in the neoadjuvant chemo-radiation treatment of locally advanced rectal cancers.

Canadian Association of Radiation Oncology Virtual Scientific Meeting 2021. 2021 October;

Concomitant use of proton pump inhibitors with capecitabine based neoadjuvant chemoradiotherapy for locally advanced rectal cancer: Is it safe?

Menon A., Abraham A.G., Mahfouz M., Thachuthara J.J., Usmani N., Warkentin H., Ghosh S., Nijjar T., Severin D., Tankel K., Paulson K., Mulder K., Roa W., Joseph K.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2021 July; 10.1097/COC.0000000000000850

Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer: A Read-world Study

Abdel-Rahman O, Mulder K, Easaw J.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2021 April; 10.10970000000000000799

Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer

Abdel-Rahman O., Koski S., Mulder K.

International Journal of Colorectal Disease. 2021 March; 36 (3):493-499 10.1007/s00384-020-03778-6

Capecitabine demonstrates improved survival benefit over 5-flurouracil in the setting of neo-adjuvant chemo-radiation for locally advanced rectal cancer patients.

Int J Radiat Oncol Biol Phys. 2020 November;

Impact of dose-capping chemotherapy in concurrent chemoradiotherapy in rectal cancer patients.

Yang R, Younis M, Joseph K, Ghosh S, Nijjar T, Severin D, Tankel K, Tamhane Y, Fairchild AM, Spratlin JL, Mulder K, Usmani N.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2020 October; 10.1177/1078155220962192